Ezetimibe (Zetia)

An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.

Also Known As:

Networked: 1626 relevant articles (237 outcomes, 538 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tershakovec, Andrew M: 41 articles (10/2021 - 09/2006)
2.	Wachtell, Kristian: 40 articles (01/2022 - 04/2007)
3.	Gerdts, Eva: 39 articles (01/2021 - 04/2007)
4.	Boman, Kurt: 33 articles (12/2019 - 04/2007)
5.	Ray, Simon: 32 articles (01/2021 - 04/2007)
6.	Ballantyne, Christie M: 28 articles (12/2021 - 05/2003)
7.	Cannon, Christopher P: 26 articles (10/2021 - 08/2014)
8.	Rossebø, Anne B: 25 articles (01/2022 - 04/2007)
9.	Cramariuc, Dana: 25 articles (01/2021 - 02/2008)
10.	Farnier, Michel: 25 articles (09/2019 - 07/2005)

Related Diseases

1.	Hypercholesterolemia 03/01/2018 - "Ezetimibe monotherapy (10 mg/day) showed a small (7.06%) but statistically significant reduction in the plasma levels of Lp(a) in patients with primary hypercholesterolemia. " 01/01/2011 - "Therefore, the objective in this study was to clarify the vascular protective effects of ezetimibe in patients with hypercholesterolemia. " 01/01/2012 - "The aims of our study were to examine the efficacy of ezetimibe for hypercholesterolemia and its pleiotropic effects. " 04/01/2003 - "This randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of ezetimibe 10 mg/day in patients with primary hypercholesterolemia. " 01/01/2011 - "Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress."
2.	Dyslipidemias (Dyslipidemia) 11/01/2008 - "Ezetimibe has proved effective for the treatment of dyslipidemia in these patients. " 11/01/2010 - "The current evidence suggests that the addition of ezetimibe to satin is effective and safe in treating dyslipidemia in the CKD and the kidney transplant patients. " 06/01/2010 - "In the present study, we evaluated the efficacy of 6 months of ezetimibe treatment for NASH patients with dyslipidemia for the comparison of improvement of the clinical parameters and histological alterations. " 06/01/2015 - "Eight patients with dyslipidemia enrolled in this study completed blood and bile sampling before and at 3 months after ezetimibe treatment (10 mg/day), and the samples are analyzed. " 02/18/2015 - "In vitro studies using NPC1L1-overexpressing intestinal cells and in vivo studies with Npc1l1-knockout mice revealed that intestinal VK absorption is NPC1L1-dependent and inhibited by ezetimibe, an NPC1L1-selective inhibitor clinically used for dyslipidemia. "
3.	Acute Coronary Syndrome 11/01/2015 - "Although 31.6% of patients would qualify for ezetimibe, there is a large potential for an increase in ezetimibe use in acute coronary syndrome outside of the strict trial inclusions. " 01/01/2021 - "Little is known of the acute effects of ezetimibe in patients with acute coronary syndrome (ACS) undergoing PCI. " 01/01/2019 - "Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT)." 11/01/2015 - "Of 219,625 patients with acute coronary syndrome, 69,508 (31.6%) would qualify for ezetimibe on the basis of strict criteria. " 11/01/2015 - "We identified patients with acute coronary syndrome from the Veterans Affairs health care system over a 5-year period and determined what proportion would be candidates for ezetimibe on the basis of IMPROVE-IT criteria. "
4.	Type 2 Diabetes Mellitus (MODY) 12/01/2018 - "The benefit of ezetimibe is consistent in patients with and without polyvascular disease and type 2 diabetes; however, by nature of their higher risk patients with one, or especially both, of these diseases might derive the greatest absolute benefits. " 03/28/2012 - "Therefore, we compared HbA1c levels after 3 months ezetimibe treatment with baseline levels in patients with type 2 diabetes and examined the factors associated with reductions in HbA1c following ezetimibe administration. " 07/01/2011 - "By a double blind cross-over design 15 subjects with type 2 diabetes and hypercholesterolaemia followed in random order a 6-week treatment with ezetimibe 10mg+simvastatin 20 mg (EZE+S) or placebo+simvastatin 20 mg (P+S) and, after a 6-week wash-out period, crossed over to the other treatment (NCT00699023). " 10/01/2010 - "Therefore, we propose that ezetimibe may be a promising therapeutic drug for obese and type 2 diabetes." 12/01/2009 - "Ezetimibe has been more particularly studied in patients with type 2 diabetes whose high cardiovascular risk is well known. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 11/01/2010 - "Although there is a growing push for the continued use of ezetimibe for the prevention of cardiovascular disease, ezetimibe studies available so far are inconsistent, without allowing use of the drug with confidence." 12/01/2009 - "Studies with larger sample sizes and follow-up beyond 12 weeks remain necessary to further define the impact of ezetimibe on the processes integral to the pathogenesis and progression of cardiovascular disease." 01/01/2009 - "Ezetimibe has not been evaluated in large clinical trials with cardiovascular disease (CVD) endpoints. " 11/19/2018 - "Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events." 02/01/2016 - "The Role of Ezetimibe in the Treatment of Cardiovascular Disease."

Related Drugs and Biologics

1.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2.	Lipids
3.	Simvastatin (Zocor)
4.	oxidized low density lipoprotein
5.	LDL Cholesterol
6.	Simvastatin Drug Combination Ezetimibe (Vytorin)
7.	Cholesterol
8.	Rosuvastatin Calcium (Crestor)
9.	Atorvastatin (Lipitor)
10.	Fenofibrate (CiL)

Related Therapies and Procedures

1.	Therapeutics
2.	Blood Component Removal (Apheresis)
3.	Secondary Prevention
4.	Stents
5.	Transplantation